1,000 Shares in Danaher Co. (NYSE:DHR) Bought by Cetera Trust Company N.A

Cetera Trust Company N.A purchased a new position in Danaher Co. (NYSE:DHR) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,000 shares of the conglomerate’s stock, valued at approximately $231,000.

Several other hedge funds and other institutional investors have also made changes to their positions in DHR. Banco Santander S.A. purchased a new position in Danaher during the 3rd quarter valued at approximately $683,000. First Citizens Bank & Trust Co. raised its position in shares of Danaher by 0.6% during the 4th quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock valued at $6,156,000 after buying an additional 149 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Danaher by 48.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock valued at $68,707,000 after acquiring an additional 96,395 shares during the last quarter. Parkside Financial Bank & Trust grew its position in Danaher by 4.8% in the third quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock worth $764,000 after acquiring an additional 142 shares in the last quarter. Finally, Keybank National Association OH increased its stake in Danaher by 0.5% during the third quarter. Keybank National Association OH now owns 553,155 shares of the conglomerate’s stock worth $137,238,000 after acquiring an additional 2,567 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Insider Activity

In other Danaher news, SVP Daniel Raskas sold 23,757 shares of the firm’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the sale, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at $9,601,704. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, Director Walter G. Lohr sold 3,289 shares of Danaher stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $251.15, for a total value of $826,032.35. Following the sale, the director now directly owns 14,129 shares in the company, valued at approximately $3,548,498.35. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total value of $5,986,764.00. Following the transaction, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at approximately $9,601,704. The disclosure for this sale can be found here. Insiders have sold 32,957 shares of company stock worth $8,265,802 in the last ninety days. Company insiders own 10.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on DHR. Barclays raised their price objective on Danaher from $240.00 to $260.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 10th. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Citigroup increased their target price on Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Raymond James lifted their price objective on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Finally, HSBC raised Danaher from a “hold” rating to a “buy” rating and upped their target price for the company from $250.00 to $280.00 in a research report on Wednesday, April 17th. Six analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $268.27.

Danaher Stock Up 0.8 %

Danaher stock opened at $237.49 on Monday. The business’s 50-day moving average price is $248.94 and its 200 day moving average price is $230.25. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. The firm has a market cap of $175.87 billion, a price-to-earnings ratio of 36.86, a price-to-earnings-growth ratio of 3.95 and a beta of 0.83. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $259.00.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.18. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The business had revenue of $6.41 billion for the quarter, compared to analysts’ expectations of $6.10 billion. During the same quarter last year, the company earned $2.87 EPS. The business’s revenue was down 10.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Danaher Co. will post 7.62 earnings per share for the current year.

Danaher Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be paid a dividend of $0.27 per share. This is a positive change from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. The ex-dividend date of this dividend is Wednesday, March 27th. Danaher’s dividend payout ratio is presently 16.90%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.